Findings also suggest increased risk of mortality and new arrhythmia; authors stress need for randomized trials
A large, multinational, observational registry analysis “found no evidence of benefit” on in-hospital outcomes for the use of hydroxychloroquine or chloroquine, either alone or with a macrolide, in treating COVID-19, according to paper published online Friday in The Lancet.